Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170157 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT00170157 is a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma that has completed, run by Mayo Clinic. The registered enrollment target is 112 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00170157, a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Bicalutamide
- DRUG Goserelin Acetate
- DRUG Leuprolide Acetate
- DRUG Flutamide
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170157
The ClinicalTrials.gov registry entry for NCT00170157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (48% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Ipilimumab is the first listed.
NCT00170157 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00170157 about?
NCT00170157 is a clinical study titled "Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some b...
What is the current status of trial NCT00170157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2004-06. Estimated completion is 2013-06.
What conditions does trial NCT00170157 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Stage III Prostate Cancer.
What interventions are being tested in trial NCT00170157?
The interventions under investigation include: Ipilimumab (DRUG), Bicalutamide (DRUG), Goserelin Acetate (DRUG), Leuprolide Acetate (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT00170157?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00170157 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.